Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV007 Intravitreal Gel in Neovascular AMD
NCT04422899Phase 1Completed
- Sponsor
- AiViva BioPharma
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AIV007 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by AiViva BioPharma. Primary endpoint: Adverse Events at 224 days. Started Aug 2020; status: completed.
02
Drugs
AIV007
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04422899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422899.